P2Y12 inhibitors may be superior to aspirin for secondary CVD prevention -

In patients requiring secondary CVD prevention, P2Y12 inhibitor monotherapy conferred reduced risk for major adverse CV events compared with aspirin monotherapy without raising risk for bleeding, researchers reported.The researchers conducted a meta-analysis of nine trials — five comparing clopidogrel with aspirin and four comparing ticagrelor (Brilinta, AstraZeneca) with aspirin —